Tag Archives: Daclatasvir

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

MSF responds to BMS access plans on hep C drug daclatasvir

Source: MSF Access Campaign Background Pharmaceutical company Bristol-Myers Squibb (BMS) has recently revealed a restrictive commercial strategy for sales of its new direct-acting antiviral (DAA) hepatitis C drug daclatasvir in developing countries. This new generation of drugs to treat hepatitis … Continue reading

Posted in IP Rights, Patents, Pricing, Voluntary License | Tagged , | Leave a comment

MSF responds to European approval of hepatitis C drug daclatasvir

On 27 August 2014, the European Commission (EC) and the European MedicinesAgency (EMA) became the second stringent regulatory authority (after Japanin July) to approve new direct-acting antiviral (DAA) daclatasvir, used totreat hepatitis C. Daclatasvir is the third DAA – a … Continue reading

Posted in Hepatitis C, Price Negotiations, Right to Health | Tagged , , , , , , | Leave a comment